Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to catch Alzheimer's sooner by looking at the whole person

NCT ID NCT07399418

Knowledge-focused Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The TRIAD study is testing whether combining biological markers, psychological tests, and social factors can help diagnose Alzheimer's disease earlier and more accurately. Researchers will follow 80 patients with cognitive decline and their caregivers, collecting data through memory tests, blood samples, brain scans, and questionnaires. The goal is to create a more complete picture of the disease to improve early detection and care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better early detection tools for Alzheimer's disease by integrating multiple risk factors.
What could go wrong
This is an observational study with only 80 participants, so results may not apply to everyone. It aims to gather knowledge, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Outpatients and their caregivers will be enrolled at the Center for Cognitive Disorders and Dementia (CDCD) of the ICS Maugeri IRCCS in Montescano, within the Neurophysiopathology Unit and the diagnostic-therapeutic pathway for dementia (DTCP - Diagnostic-Therapeutic Care Pathway for Dementia).

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (patients): * Age ≥ 50 years. * Presence of a primary caregiver, i.e., a person who provides regular care and who can actively participate in the study. * Understanding of the research objectives and ability to provide informed consent. Inclusion Criteria (caregivers): * Be the primary caregiver, providing care for at least six months. * Age ≥ 18 years, to ensure the ability to understand and actively participate in the study. * Understanding of the research objectives and ability to provide informed consent. Exclusion Criteria (patients): * Age under 50. * History of previous or concomitant neurological disorders (e.g., severe cerebrovascular accidents, brain tumors, traumatic injuries affecting cognitive functions) and neurodegenerative disorders. * History of major psychiatric disorders (e.g., schizophrenia, severe bipolar disorder, untreated major depression), alcohol or substance abuse. * Medical conditions that may interfere with cognitive function (e.g., advanced renal or hepatic failure, severe respiratory disorders, untreated hypothyroidism, B12 deficiency). * Decompensated systemic diseases with clinical instability and significant organ failure. * Marked sensory limitations (hearing or vision) and/or language difficulties. * Participation in other experimental studies involving previous or current involvement in clinical trials of anti-amyloid drugs or experimental drug treatments for AD in the previous 6 months. Exclusion Criteria (caregivers): * Presence of severe active psychiatric disorders (e.g., untreated major depression, psychotic disorder, or schizophrenia). * Difficulty participating in interviews and assessments due to language barriers, cognitive deficits, or other personal limitations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ICS Maugeri Montescano Institute

    RECRUITING

    Montescano, Pavia, Italy, 27040, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.